Laboratory Workup for Shuffling Gait
Order a comprehensive metabolic panel (including blood glucose), complete blood count, erythrocyte sedimentation rate, thyroid function tests, serum B12 with metabolites (methylmalonic acid and homocysteine), and serum protein immunofixation electrophoresis as your initial laboratory screening for shuffling gait. 1
Rationale for Laboratory Testing
Shuffling gait is a clinical sign that can result from multiple etiologies, most notably Parkinson's disease and distal symmetric polyneuropathy (DSP). 2 While the diagnosis relies primarily on clinical examination and pattern recognition, laboratory testing is essential to identify treatable underlying causes and exclude mimics. 1
Core Laboratory Panel
The following tests should be ordered for all patients presenting with shuffling gait:
Blood glucose/HbA1c: Diabetes mellitus is the most common cause of polyneuropathy, with elevated blood glucose found in approximately 11% of DSP patients. 1 This is the highest-yield screening test.
Complete blood count (CBC): Screens for anemia, infection, and hematologic disorders that may contribute to neuropathy. 1
Comprehensive metabolic panel: Assesses renal function, liver function, and electrolyte abnormalities that can cause or contribute to gait disturbance. 1
Erythrocyte sedimentation rate (ESR): Screens for inflammatory and autoimmune conditions. 1
Thyroid function tests (TSH, free T4): Hypothyroidism can cause both neuropathy and parkinsonian features. 1
Serum B12 with metabolites: Vitamin B12 deficiency causes polyneuropathy in 2.2-8% of cases. 1 Critically, order methylmalonic acid and homocysteine in addition to serum B12, as 44% of B12-deficient patients have normal B12 levels but elevated metabolites. 1 Methylmalonic acid is more specific than homocysteine (elevated in 98.4% vs 95.9% of B12 deficiency). 1
Serum protein immunofixation electrophoresis: Abnormal in approximately 9% of DSP patients, identifying paraproteinemic neuropathies. 1
Key Clinical Pitfall
Do not rely on serum B12 alone—approximately 44% of patients with B12-deficient polyneuropathy have B12 levels in the low-normal range (200-500 pg/dL) and are only identified through elevated methylmalonic acid and homocysteine. 1 Missing this treatable cause of neuropathy has significant implications for morbidity and quality of life.
Additional Considerations
Electrodiagnostic studies: While not a "laboratory test," nerve conduction studies and EMG are essential complements to laboratory workup when polyneuropathy is suspected, as they confirm the diagnosis and characterize the pattern. 1
Cerebrospinal fluid analysis: Has low diagnostic yield except in demyelinating polyneuropathies and should not be routinely ordered unless clinical suspicion warrants it. 1
Genetic testing: Not part of initial screening but may be indicated based on clinical presentation and family history. 1
Diagnostic Yield
When combined with history, neurological examination, and electrodiagnostic studies, this laboratory panel yields an etiological diagnosis in 74-82% of polyneuropathy cases. 1 However, laboratory tests alone have limited specificity (37% diagnostic yield when used in isolation), emphasizing the importance of clinical context. 1